Home » Stocks » OPGN

OpGen, Inc. (OPGN)

Stock Price: $2.33 USD 0.04 (1.75%)
Updated Jan 22, 2021 1:03 PM EST - Market open
Market Cap 51.50M
Revenue (ttm) 3.68M
Net Income (ttm) -21.62M
Shares Out 19.12M
EPS (ttm) -1.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $2.33
Previous Close $2.29
Change ($) 0.04
Change (%) 1.75%
Day's Open 2.31
Day's Range 2.27 - 2.43
Day's Volume 895,659
52-Week Range 1.42 - 4.04

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

GAITHERSBURG, Md., Jan. 13, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help ...

GlobeNewsWire - 2 weeks ago

GAITHERSBURG, Md. and HOLZGERLINGEN, Germany, Jan. 05, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics ...

GlobeNewsWire - 1 month ago

Dr. Arne Materna to join Ares Genetics as new Managing Director and CEO to lead Ares into next phase of its growth  

GlobeNewsWire - 1 month ago

Extended collaboration with leading global generics company Sandoz for optimal antibiotic drug positioning by predictive antibiotic susceptibility testing

GlobeNewsWire - 1 month ago

GAITHERSBURG, Md., Nov. 24, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help ...

GlobeNewsWire - 2 months ago

Early access program launched for the next generation of the ARESupa Universal Pathogenome Assay based on targeted next-generation sequencing (NGS) of native specimens

Seeking Alpha - 2 months ago

OpGen, Inc. (OPGN) CEO Oliver Schacht on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

Conference call to be held at 4:30 p.m. Eastern Time today

GlobeNewsWire - 2 months ago

GAITHERSBURG, Md., Oct. 29, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its third ...

GlobeNewsWire - 2 months ago

GAITHERSBURG, Md. and HOLZGERLINGEN, Germany, Oct. 28, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics ...

GlobeNewsWire - 3 months ago

GAITHERSBURG, Md., Oct. 15, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help ...

GlobeNewsWire - 3 months ago

GAITHERSBURG, Md., Oct. 13, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help ...

GlobeNewsWire - 3 months ago

Ares Genetics wins Austrian Digitization Award for Digital Products and Solutions

GlobeNewsWire - 3 months ago

GAITHERSBURG, Md. and HOLZGERLINGEN, Germany, Sept. 28, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnosti...

GlobeNewsWire - 4 months ago

GAITHERSBURG, Md., Sept. 18, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”) announced today that it has changed the venue of its 2020 Annual Meeting of Stockho...

GlobeNewsWire - 4 months ago

Published Study on Modifiable Risk Factors for the Emergence of Ceftolozane-Tazobactam Resistance

GlobeNewsWire - 4 months ago

Ares Genetics nominated for the 40th Austrian Innovation Award by Federal Ministry for Digital and Economic Affairs

GlobeNewsWire - 4 months ago

GAITHERSBURG, Md., and HOLZGERLINGEN, Germany, Sept. 02, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnost...

Benzinga - 5 months ago

OpGen (NASDAQ: OPGN) shares are trading higher after the company announced its subsidiary obtained the CE mark certification in the European Union for its own SARS-CoV-2 Kit with PULB detectio...

Market Watch - 5 months ago

Shares of Maryland-based OpGen Inc. OPGN, -0.96% rocketed 43% in active premarket trading Thursday, after the molecular diagnostics company said its Germany-based Curetis GmbH subsidiary obtai...

GlobeNewsWire - 5 months ago

- Own developed SARS-CoV-2 Kit with PULB for COVID-19 uses real-time PCR (RT-PCR) technology on open PCR platforms, designed to provide results in approximately one hour

Seeking Alpha - 5 months ago

OpGen, Inc. (OPGN) CEO Oliver Schacht on Q2 2020 Results - Earnings Call Transcript

Benzinga - 5 months ago

Shares of OpGen (NASDAQ:OPGN) rose 4.98% in after-market trading after the company reported Q2 results.

GlobeNewsWire - 5 months ago

Conference call to be held at 4:30 p.m. Eastern Time today

Benzinga - 5 months ago

OpGen (NASDAQ: OPGN) will be releasing its next round of earnings this Wednesday, August 12.

GlobeNewsWire - 5 months ago

Accurate identification of antibiotic resistance markers based on the ARESdb QIAGEN CLC Module leveraging Ares Genetics’ proprietary antibiotic resistance database

GlobeNewsWire - 5 months ago

GAITHERSBURG, Md., Aug. 09, 2020 (GLOBE NEWSWIRE) -- As disclosed in OpGen, Inc.’s (NASDAQ: OPGN) (“OpGen” or “the Company”) July 13, 2020 press release, we have commenced marketing and prom...

GlobeNewsWire - 5 months ago

GAITHERSBURG, Md., Aug. 05, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its seco...

GlobeNewsWire - 6 months ago

GAITHERSBURG, Md., July 15, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN)(“OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help c...

GlobeNewsWire - 6 months ago

Strategic partnership will focus on commercializing CELLSEARCH platform for COVID-19 related use cases, along with other COVID-19 related products Strategic partnership will focus on commercia...

GlobeNewsWire - 6 months ago

-  European Investment Bank (EIB) and OpGen, Curetis GmbH and Ares Genetics GmbH enter into Amendment to the EIB Financing Agreement

Forbes - 6 months ago

If you’re looking for some hedges for your portfolio or are looking to shift against the market, our deep learning algorithms and AI technology have several Top Shorts for you today.

Other stocks mentioned: AGEN, AMRS, INSE, RTIX
Benzinga - 7 months ago

OpGen (NASDAQ: OPGN) shares are trading higher after the company announced its Unyvero HPN Panel identifies bacterial co-infections in hospitalized patients with COVID-19 pneumonia in just fiv...

GlobeNewsWire - 7 months ago

GAITHERSBURG, Md. and HOLZGERLINGEN, Germany, June 09, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostic...

GlobeNewsWire - 8 months ago

GAITHERSBURG, Md., May 11, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help co...

Seeking Alpha - 8 months ago

OpGen, Inc. (OPGN) CEO Oliver Schacht on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 9 months ago

- Investigator initiated study at Sweden’s Karolinska Institutet to test COVID-19 pneumonia patients with Unyvero HPN panel for bacterial co-infections

GlobeNewsWire - 9 months ago

Peer-reviewed study evaluated performance of AI-powered bioinformatics cloud platform, ares-genetics.cloud, for NGS-based antibiotic susceptibility testing on 12 pathogenic bacterial species a...

GlobeNewsWire - 9 months ago

Following strong support from shareholders, OpGen and Curetis consummated their business combination transaction

GlobeNewsWire - 9 months ago

Vote approving transaction passes with 95% support for the transaction

Seeking Alpha - 9 months ago

OpGen, Inc. (OPGN) CEO Evan Jones on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 9 months ago

Shareholder proxy vote achieves quorum with 99% support for the transaction

GlobeNewsWire - 9 months ago

In an analysis of K. pneumoniae bacterial isolates, an overall agreement of 95.6% was observed between phenotypic antimicrobial susceptibility and genotypic prediction by OpGen’s Acuitas Light...

GlobeNewsWire - 10 months ago

Shareholder proxy vote stands at 97% of the required quorum with support for the transaction at over 95% Shareholder proxy vote stands at 97% of the required quorum with support for the transa...

InvestorPlace - 10 months ago

OpGen (OPGN) news for Monday includes OPGN stock taking off following an update on test kits for the coronavirus from China. The post OpGen (OPGN) Stock Skyrockets 128% on Rapid Coronavirus Te...

Benzinga - 10 months ago

OpGen Inc (NASDAQ: OPGN) shares were ripping higher Monday in reaction to an announcement regarding a COVID-19 test kit from German molecular diagnostics company Curetis, which OpGen has agree...

GlobeNewsWire - 10 months ago

- Rapid real-time PCR test allows testing for SARS-CoV2 in only a few hours

GlobeNewsWire - 11 months ago

Revenue increases by 64% to EUR 2.3 million, up from 1.4 million in 2018

GlobeNewsWire - 11 months ago

GAITHERSBURG, Md., Feb. 12, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help ...

24/7 Wall Street - 11 months ago

OpGen Inc. (NASDAQ: OPGN) shares jumped on Thursday after the company announced that it will be joining the fight against the coronavirus (2019-nCov).

About OPGN

OpGen, a precision medicine company, engages in developing molecular information products and services in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. The company's products include Acuitas AMR Gene Panel, a vitro diagnostic test for the detection and identification of vari... [Read more...]

Industry
Diagnostics & Research
IPO Date
May 5, 2015
CEO
Oliver Schacht
Employees
38
Stock Exchange
NASDAQ
Ticker Symbol
OPGN
Full Company Profile

Financial Performance

In 2019, OpGen, Inc.'s revenue was $3.50 million, an increase of 18.75% compared to the previous year's $2.95 million. Losses were -$12.45 million, -6.89% less than in 2018.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for OpGen, Inc. stock is "Buy." The 12-month stock price forecast is 4.83, which is an increase of 107.30% from the latest price.

Price Target
$4.83
(107.30% upside)
Analyst Consensus: Buy